|
 |
|
|
| |
Heart attack |
A heart attack (also
known as a myocardial infarction) is the death of heart muscle from the
sudden blockage of a coronary artery by a blood clot. Coronary arteries
are blood vessels that supply the heart muscle with blood and oxygen.
Blockage of a coronary artery deprives the heart muscle of blood and oxygen,
causing injury to the heart muscle. Injury to the heart muscle causes
chest pain and pressure. If blood flow is not restored within 20 to 40
minutes, irreversible death of the heart muscle will begin to occur. Muscle
continues to die for 6-8 hours at which time the heart attack usually
is "complete." The dead heart muscle is replaced by scar tissue.
Approximately one million Americans suffer a heart attack each year. Four
hundred thousand of them die as a result of their heart attack.
|
|
Dosage |
Packing |
Price |
Pay now |
75 mg |
100 tab |
USD 59.00 |
|
|
|
 |
What are the symptoms
of a heart attack? |
|
Although chest pain or pressure
is the most common symptom of a heart attack, heart attack victims may
experience a diversity of symptoms that include:
• Pain, fullness, and/or squeezing sensation of the chest
• Jaw pain, toothache, headache
• Shortness of breath
• Nausea, vomiting, and/or general epigastric (upper middle abdomen)
discomfort
• Sweating
• Heartburn and/or indigestion
• Arm pain (more commonly the left arm, but may be either arm)
• Upper back pain
• General malaise (vague feeling of illness)
• No symptoms (Approximately one quarter of all heart attacks are
silent, without chest pain or new symptoms. Silent heart attacks are especially
common among patients with diabetes mellitus)
Even though the symptoms of a heart attack at times can be vague and mild,
it is important to remember that heart attacks producing no symptoms or
only mild symptoms can be just as serious and life-threatening as heart
attacks that cause severe chest pain. Too often patients attribute heart
attack symptoms to "indigestion," "fatigue," or "stress,"
and consequently delay seeking prompt medical attention. One cannot overemphasize
the importance of seeking prompt medical attention in the presence of
symptoms that suggest a heart attack. Early diagnosis and treatment saves
lives, and delays in reaching medical assistance can be fatal. A delay
in treatment can lead to permanently reduced function of the heart due
to more extensive damage to the heart muscle. Death also may occur as
a result of the sudden onset of arrhythmias such as ventricular fibrillation. |
 |
How is a
heart attack treated? |
|
Treatment of heart attacks
include:
• Anti-platelet medications to prevent formation of blood clots
in the arteries
• Anti-coagulant medications to prevent growth of blood clots in
the arteries
• Coronary angiography with either percutaneous transluminal coronary
angioplasty (PTCA) with or without stenting to open blocked coronary arteries
• Clot-dissolving medications to open blocked arteries
• Supplemental oxygen to increase the supply of oxygen to the heart's
muscle
• Medications to decrease the need for oxygen by the heart's muscle
• Medications to prevent abnormal heart rhythms
The primary goal of treatment is to quickly open the blocked artery and
restore blood flow to the heart muscle, a process called reperfusion.
Once the artery is open, damage to heart muscle ceases, and the patient
becomes pain free. By minimizing the extent of heart muscle damage, early
reperfusion preserves the pumping function of the heart. Optimal benefit
is obtained if reperfusion can be established within the first 4-6 hours
of a heart attack. Delay in establishing reperfusion can result in more
widespread damage to heart muscle and a greater reduction in the ability
of the heart to pump blood. Patients with hearts that are unable to pump
sufficient blood develop heart failure, decreased ability to exercise,
and abnormal heart rhythms. Thus, the amount of healthy heart muscle remaining
after a heart attack is the most important determinant of the future quality
of life and longevity. |
 |
Research articles |
|
Eur Heart J. 2005 Mar;26(6):576-83.
Epub 2005 Feb 21. Clopidogrel administration prior
to coronary artery bypass grafting surgery: the cardiologist's panacea or
the surgeon's headache? Kapetanakis EI, Medlam
DA, Boyce SW, Haile E, Hill PC, Dullum MK, Bafi AS, Petro KR, Corso PJ.
Section of Cardiac Surgery, Department of Surgery, Washington Hospital Center,
106 Irving Street, NW, Suite 316, Washington, DC 20010-2975, USA.
AIMS: Thrombotic complications after percutaneous coronary intervention
procedures have decreased in past years mainly due to the use of clopidogrel
antiplatelet therapy. However, the risk of bleeding due to enhanced and
irreversible platelet inhibition in patients who will require surgical coronary
revascularization instead has not been adequately addressed in the literature.
The purpose of this study was to evaluate the effect of pre-operative clopidrogel
exposure in haemorrhage-related re-exploration rates, peri-operative transfusion
requirements, morbidity, and mortality in patients undergoing coronary artery
bypass grafting (CABG) surgery. METHODS AND RESULTS: A study population
of 2359 patients undergoing isolated CABG between January 2000 and June
2002 was reviewed. Of these, 415 (17.6%) received clopidogrel prior to CABG
surgery, and 1944 (82.4%) did not. A risk-adjusted logistic regression analysis
was used to assess the association between clopidogrel pre-medication (vs.
no) and haemostatic re-operation, intraoperative and post-operative blood
transfusion rates, and multiple transfusions received. Haemorrhage-related
pre-operative risk factors identified from the literature and those found
significant in a univariate model were used. Furthermore, a sub-cohort,
matched-pair by propensity scores analysis, was also conducted. The clopidogrel
group had a higher likelihood of haemostatic re-operation [OR=4.9, (95%
CI, 2.63-8.97), P<0.01], an increase in total packed red blood cell transfusions
[OR=2.2, (95% CI, 1.70-2.84), P<0.01], multiple unit blood transfusions
[OR=1.9, (95% CI, 1.33-2.75), P<0.01] and platelet transfusions [OR=2.6,
(95% CI, 1.95-3.56), P<0.01]. Surgical outcomes and operative mortality
[OR=1.5, (95% CI, 0.36-6.51), P=0.56] were not significantly different.
CONCLUSION: Pre-operative clopidogrel exposure increases the risk of haemostatic
re-operation and the requirements for blood and blood product transfusion
during, and after, CABG surgery.
|
| | |
In general most countries have a policy which allows the importation
of up to 3 months supply of a given medication without the need
for a prescription, as long as it is for personal use. We give information
about import conditions for different countries on our page: Shipping;
but national policies are subject to change and we cannot guarantee
that this information will always be absolutely correct. You can obtain
information on the applicable importation policy by contacting your
countrys Customs authority. In 99% of cases we have experienced
no problems with secure worldwide delivery to our customers.
For safety reasons we may ship orders in separate shipments with a
timelag of 2-7 days between part-shipments.
We DO NOT supply medications generally classed as controlled substances.
|
|
|